Medically reviewed by Regenerated Medical Advisory Board

Published February 16, 2026Updated June 25, 2026

CJC-1295/Ipamorelin: Why This Growth Hormone Peptide Stack Works

CJC-1295 and Ipamorelin are two peptides that individually stimulate growth hormone release through different pathways. Combined, they produce a synergistic effect that is greater than either peptide alone. This combination has become the most widely prescribed growth hormone peptide protocol in functional and regenerative medicine, and for good reason: it offers many of the benefits of growth hormone therapy at a fraction of the cost and with a significantly better safety profile.

If you have been curious about growth hormone optimization but do not want to jump straight to synthetic HGH (which carries higher risks and costs), the CJC-1295/Ipamorelin stack is the starting point most knowledgeable practitioners recommend.

At a Glance

CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that extends the natural GH pulse signal
Ipamorelin is a growth hormone-releasing peptide (GHRP) that mimics ghrelin to trigger a GH pulse
Combined, they stimulate growth hormone through two complementary pathways, producing a stronger and more physiologic GH release than either alone
Benefits include improved body composition (less fat, more lean mass), better sleep quality, faster recovery, improved skin quality, and enhanced joint health
Available with DAC (drug affinity complex, for longer-acting effects) or without DAC (for sharper, more pulsatile GH release)
Typical protocols involve subcutaneous injections once daily (usually at bedtime) for 8 to 12 week cycles
Side effects are generally mild: water retention, occasional numbness/tingling, increased hunger with ipamorelin
Lab monitoring (IGF-1, fasting glucose) is recommended during use

Understanding the Two Peptides

CJC-1295: The GHRH Analog

Your pituitary gland releases growth hormone in pulses throughout the day, with the largest pulse occurring during deep sleep. These pulses are triggered by growth hormone-releasing hormone (GHRH), which is produced in the hypothalamus. CJC-1295 is a synthetic analog of GHRH, meaning it mimics the natural signal that tells your pituitary to release GH.¹

What makes CJC-1295 different from natural GHRH is stability. Natural GHRH is broken down in the blood within minutes. CJC-1295 has been modified to resist enzymatic degradation, giving it a much longer active life. This means each dose sustains the “release GH” signal for hours rather than minutes.

CJC-1295 comes in two forms:

CJC-1295 with DAC (Drug Affinity Complex): DAC allows the peptide to bind to albumin in the blood, extending its half-life to approximately 6 to 8 days. This creates a sustained, steady elevation of growth hormone levels. Dosed once or twice per week.
CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF): Shorter half-life of approximately 30 minutes. This produces sharper, more defined GH pulses that more closely mimic natural physiology. Dosed once or twice daily.

Ipamorelin: The Ghrelin Mimetic

Ipamorelin belongs to a different class of growth hormone secretagogues. Rather than mimicking GHRH, it mimics ghrelin, the “hunger hormone” that also triggers GH release through the growth hormone secretagogue receptor (GHS-R) in the pituitary.²

What makes Ipamorelin stand out among GH-releasing peptides is its selectivity. Older GHRPs like GHRP-6 and GHRP-2 also stimulate GH release, but they come with significant spikes in cortisol and prolactin. Ipamorelin is highly selective for GH release with minimal effect on cortisol or prolactin. This cleaner profile is why it has become the preferred GHRP for most clinical applications.

Ipamorelin also causes less intense hunger spikes compared to GHRP-6, though some appetite increase is still common (ghrelin receptors are involved in appetite signaling).

The Synergy: Why Combining Them Works Better

CJC-1295 and Ipamorelin stimulate GH release through two distinct receptor pathways:

CJC-1295 activates the GHRH receptor (amplifying the release signal)
Ipamorelin activates the GHS receptor (initiating the release pulse)

When both pathways are activated simultaneously, the pituitary releases significantly more GH than either signal alone would produce. Studies show the combination produces GH pulses 2 to 3 times larger than either peptide administered individually. This is true pharmacological synergy, not just additive effects.³

The combination also produces a more natural GH release pattern. Your body normally releases GH in pulses (not as a steady stream), and the CJC-1295 without DAC plus Ipamorelin combination preserves this pulsatile pattern. This matters because continuous GH exposure (as seen with high-dose HGH injections) can cause more side effects than pulsatile release at the same total GH output.

With DAC vs. Without DAC

CJC-1295 with DAC produces a sustained GH elevation over days. Some practitioners prefer this for convenience (less frequent dosing). The downside is that it “flattens” the natural GH pulse pattern into a more continuous elevation, which is less physiologic and may carry slightly more risk of side effects like water retention.

CJC-1295 without DAC (Mod GRF 1-29) produces sharper, shorter GH pulses that more closely resemble your body’s natural rhythm. Most experienced peptide clinicians prefer this form when combined with Ipamorelin because the pulsatile pattern appears to deliver benefits with fewer side effects.

Both forms work. The “without DAC” version combined with Ipamorelin is the more commonly recommended protocol in current clinical practice.

Benefits: What the Evidence and Clinical Experience Show

Body Composition

Improved body composition is the most consistently reported benefit. Growth hormone plays a central role in fat metabolism (particularly visceral fat) and lean muscle maintenance. Patients on CJC-1295/Ipamorelin protocols typically report:

Reduction in abdominal and visceral fat (usually noticeable by 6 to 8 weeks)
Modest increase in lean muscle mass, particularly when combined with resistance training
Improved muscle recovery between workouts
Better muscle tone and definition without significant weight change (body recomposition)

The fat loss effect is driven by GH’s lipolytic action: it signals fat cells to release stored fatty acids for energy. The lean mass preservation occurs because GH promotes protein synthesis and inhibits protein breakdown in muscle tissue.⁴

Sleep Quality

Many patients report improved sleep as one of the first noticeable benefits, often within the first 1 to 2 weeks. This makes physiological sense: the largest natural GH pulse occurs during slow-wave (deep) sleep. By amplifying this pulse, CJC-1295/Ipamorelin may enhance the restorative quality of deep sleep.

Common reports include falling asleep faster, sleeping more deeply, waking more refreshed, and having more vivid dreams (a marker of deeper sleep cycles).

Recovery and Joint Health

Growth hormone is essential for tissue repair. Patients using CJC-1295/Ipamorelin often report faster recovery from workouts, reduced joint stiffness, improved healing from minor injuries, and better exercise tolerance. Athletes and active adults frequently cite recovery benefits as their primary motivation for using this combination.⁵

Skin and Hair Quality

GH stimulates collagen production and skin cell turnover. After 2 to 3 months on a CJC-1295/Ipamorelin protocol, many patients notice improved skin thickness, better hydration, reduced fine lines, and improved hair texture. These cosmetic benefits are secondary to the tissue repair effects but are frequently reported.

CJC-1295/Ipamorelin vs. Synthetic HGH

Factor	CJC-1295/Ipamorelin	Synthetic HGH
Mechanism	Stimulates your pituitary to release your own GH	Directly provides exogenous GH
GH pattern	Pulsatile (more natural)	Bolus injection (less natural timing)
Pituitary function	Preserved; works with your own feedback loops	Can suppress natural GH production over time
GH output	Moderate increase (2 to 3x baseline pulses)	Can achieve much higher levels (dose-dependent)
Side effect risk	Lower (stays within physiologic range)	Higher at therapeutic doses (water retention, insulin resistance, joint pain, carpal tunnel)
Cost	$150 to $400/month (compounding pharmacy)	$600 to $3,000+/month
Prescription required	Yes	Yes
Monitoring needed	IGF-1, fasting glucose (periodic)	IGF-1, fasting glucose, insulin, HbA1c (more frequent)
Best for	Optimization, anti-aging, mild to moderate GH decline	Significant GH deficiency, specific clinical indications

The key advantage of CJC-1295/Ipamorelin over synthetic HGH is that it works through your body’s own regulatory system. Your pituitary still controls how much GH is released, and your feedback loops remain intact. This makes overshoot less likely compared to injecting a fixed dose of exogenous HGH. The tradeoff is that the GH output is more modest, which means the effects are real but subtler than what aggressive HGH dosing can achieve.⁶

Dosing Protocols

Standard CJC-1295/Ipamorelin Protocol

CJC-1295 without DAC (Mod GRF 1-29): 100 to 300 mcg per injection

Ipamorelin: 100 to 300 mcg per injection

Combined dose: Typically administered together in the same syringe, subcutaneously

Timing: Once daily, injected 30 to 60 minutes before bedtime on an empty stomach (food, particularly carbohydrates and fats, blunts GH release)

Cycle length: 8 to 12 weeks on, followed by 4 to 6 weeks off

Alternative timing: Some protocols add a morning dose (upon waking, before eating) for enhanced results. The bedtime dose is more important if only dosing once daily.

Important Dosing Notes

Empty stomach is critical: Insulin suppresses GH release. Eating (especially carbohydrates) within 30 to 60 minutes of injection reduces the GH pulse significantly. Inject at least 2 hours after your last meal.
Bedtime dosing capitalizes on natural physiology: Your largest natural GH pulse occurs during early deep sleep. Injecting before bed amplifies this pulse.
Cycling prevents desensitization: Continuous use without breaks can lead to reduced pituitary responsiveness. The 4 to 6 week break allows receptor sensitivity to reset.
Start low: Begin at the lower dose range (100 mcg each) and increase after 2 weeks if well tolerated and if blood work supports continuation.

Side Effects

CJC-1295/Ipamorelin is generally well-tolerated, especially compared to synthetic HGH. Common side effects include:

Water retention: Mild fluid retention is the most common side effect, particularly in the first 2 to 4 weeks. It typically presents as slight puffiness in the hands, feet, or face. Usually resolves as the body adjusts or responds to dose reduction.
Numbness and tingling: Occasional tingling or numbness in the extremities (hands, feet), related to fluid shifts around nerves. More common at higher doses.
Increased hunger: Ipamorelin activates ghrelin receptors, which can increase appetite. This is usually mild (less intense than GHRP-6) but notable for patients trying to lose body fat.
Injection site reactions: Mild redness, itching, or a small welt at the injection site. Rotating injection sites helps minimize this.
Headache: Occasional, usually mild, more common during the first week.
Vivid dreams: Frequently reported. Not harmful but can be intense for some users.

Who Should Avoid CJC-1295/Ipamorelin

Active cancer or history of cancer within the past 5 years: GH promotes cell growth and angiogenesis. While GH peptides do not cause cancer, they could theoretically accelerate the growth of existing tumors. This is the most important contraindication.
Diabetic retinopathy: GH can worsen diabetic eye disease by promoting abnormal blood vessel growth in the retina.
Uncontrolled diabetes: GH has anti-insulin effects and can worsen blood sugar control. Well-managed diabetics can potentially use these peptides with close monitoring, but uncontrolled diabetes is a contraindication.
Pituitary tumors or disorders: Stimulating a pituitary that has a tumor or structural abnormality carries risk.
Pregnancy and breastfeeding: No safety data available.
Children and adolescents: GH peptides should not be used outside of specialist endocrinology care in pediatric patients.

Lab Monitoring

Responsible use of CJC-1295/Ipamorelin requires baseline and follow-up blood work. Key labs include:

IGF-1 (insulin-like growth factor 1): The best single marker of overall GH activity. Check at baseline, then 4 to 6 weeks into the protocol. Target range is typically the upper third of the age-adjusted normal range. Levels above the normal range indicate the dose should be reduced.
Fasting glucose and insulin: GH has anti-insulin effects. Monitor for any worsening of blood sugar regulation, especially in patients with pre-existing insulin resistance or metabolic syndrome.
HbA1c: Check at baseline and after 3 months if the protocol extends that long.
Complete metabolic panel: Standard safety monitoring.

If IGF-1 rises above the normal range, reduce the dose or extend the off-cycle period. The goal is optimization within physiologic parameters, not pushing GH levels to supraphysiologic territory.⁷

Cost

CJC-1295/Ipamorelin is typically obtained through compounding pharmacies with a prescription. Cost varies by pharmacy and region but generally falls in the range of $150 to $400 per month. This includes the combined peptide vial, syringes, and alcohol prep supplies. Some clinics offer monthly membership packages that include the peptides, lab monitoring, and follow-up consultations.

Compared to synthetic HGH ($600 to $3,000+ per month), the cost advantage is substantial, which is one reason this combination has become the entry point for most patients exploring GH optimization.

References

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhatt RS. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
Jorgensen JO, Pedersen SA, Thuesen L, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. 1989;1(8649):1221-1225. doi:10.1016/S0140-6736(89)92328-3
Svensson J, Fowelin J, Landin K, Bengtsson BA, Johansson JO. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab. 2002;87(5):2121-2127. doi:10.1210/jcem.87.5.8482
Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146(2):104-115. doi:10.7326/0003-4819-146-2-200701160-00005
Hoffman AR, Kuntze JE, Baptista J, et al. Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89(5):2048-2056. doi:10.1210/jc.2003-030346

CJC-1295/Ipamorelin: The Growth Hormone Peptide Stack Explained

CJC-1295/Ipamorelin: Why This Growth Hormone Peptide Stack Works

At a Glance